Company Overview

Development Stage

About the Company

[Summary] 致力于在肿瘤、乙肝及与衰老相关的疾病等治疗领域开发创新药物

亚盛医药是一家立足中国、面向全球的生物医药企业,于2019年10月28日在香港联交所主板挂牌上市,股票代码:6855.HK。

作为中国*早开始原创新药研发的企业之一,亚盛医药致力在肿瘤、乙肝及与衰老相关的疾病等治疗领域开发创新药物,并始终坚持以患者为中心的全球创新战略。公司所有在研项目均为新化合物结构的原创新药,旨在瞄准中国乃至全球患者“无药可医、尚未满足”的临床需求,以填补国内空白,并惠及全球患者。

目前,亚盛医药已经打造了一支具有强大的原创新药研发与临床开发经验的国际化人才团队,和在血液肿瘤领域拥有丰富经验的商业化团队。未来,公司将进一步加速在研产品的全球临床开发和商业化进度,让更多患者更早获益。

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

Financing History (1 rounds)

Manage
战略投资
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Amount: 7500万美元
  • Investor: Takeda武田制药

How Fast Is Hiring Growing? (82 open positions)

Manage
Note: How fast is hiring at 苏州亚盛药业有限公司 growing? 2025: 103 openings (up 836%), 2024: 11 openings (down 52%), 2023: 23 openings (down 62%), 2022: 61 openings (down 63%), 2021: 165 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

Master's Degree Job Demand Analysis

(More)
?
Growth Rate
2026 vs 2025
  • 2025: Up 1500%
  • 2022: Down 50%
Master's Hiring by Year:
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is master's hiring at 苏州亚盛药业有限公司 growing? Master's recruitment over the years: 2025: 16 openings (up 1500%), 2024: 1 openings, 2022: 12 openings (down 50%), 2021: 24 openings.

Doctoral Degree Job Demand Analysis

(More)
+60%
Growth Rate
2026 vs 2025
Doctoral Hiring by Year: 2026 — 6 more jobs than 2025
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is doctoral hiring at 苏州亚盛药业有限公司 growing? Doctorate recruitment over the years: 2026: 16 openings (up 144%), 2025: 10 openings (up 1500%), 2023: 1 openings, 2022: 6 openings (down 50%), 2021: 5 openings.

R&D Strength (Technical Talent Demand)

(More)
How is the demand for technical talent at 苏州亚盛药业有限公司? Based on an analysis of 's job postings over the past year, "医疗卫生/美容保健类" demand: 44.9%, "生物/制药/化工/环保类": 12.4%, "电子/电器/通信技术类": 9.4%, "计算机/网络/技术类": 5.1%, "其他(研发和技术类)": 2.6%, "科研类": 2.1%. For reference only.

— What Are the Salaries Like? (234 records)

Manage
salary range: 3K - 50K, 55.6% of roles pay ¥20-50K
Note: salary statistics are based on 234 salary records from the past year and depend on the job sample. For reference only.
How is the salary at 苏州亚盛药业有限公司?55.6% of positions earn 20-50K, Fresh graduate salary: ¥4.1K。Suzhou salary ranking top 20,医疗卫生/美容保健类 average salary ¥32.6K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of

(More)
Are salaries high at 苏州亚盛药业有限公司? We provide: 临床,医药代表,质量,te,ma,副总,msl,市场,cto,ir,大客户,客户经理,oc,安全,医师,地区经理,控制经理,高级经理,bp,准入经理. Click to view detailed salary analysis by job.

This company — Fortune 500? (More)

honors, qualifications & industry associations

Tags are labelled based on keyword text matching analysis and may be related to the company. For reference only.

Related Industry Tags

Job Category

  • 医疗卫生/美容保健类
    43.8% of total 43.8%
  • 销售类
    34.6% of total 34.6%
  • 经营管理类
    20.8% of total 20.8%
  • 生物/制药/化工/环保类
    12.1% of total 12.1%

Education

  • 本科
    60.8% of total 60.8%
  • 硕士
    21.7% of total 21.7%
  • 博士
    10.4% of total 10.4%
  • 大专
    4.6% of total 4.6%

Experience

  • 5-10年
    42.1% of total 42.1%
  • 3-5年
    37.1% of total 37.1%
  • 1-3年
    12.1% of total 12.1%
  • 不限
    7.1% of total 7.1%
View Detailed Analysis

What does 苏州亚盛药业有限公司 require? Who is 苏州亚盛药业有限公司 hiring? recruitment: 医疗卫生/美容保健类占比最多占43.8%,其次是销售类占34.6%. What education can get in at ? 本科占比最多占60.8%,其次是硕士占21.7%. High education required at ? 硕士占21.7%,博士占10.4%. Work experience required at ? 5-10年占比最多占42.1%,其次是3-5年占37.1%. Where are the job locations at ? 苏州占比最多占23.3%,其次是上海占18.8%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 200,000万(元)
Legal Representative: Dajun Yang
Date Established:
Credit Code: 91320594MA1MLQHB2Q
Registered Address: 中国(江苏)自由贸易试验区苏州片区苏州工业园区新庆路68号

Partners & Suppliers

澎立生物为亚盛医药提供临床前药效评价服务 Source
供应商 制药企业
合作开发抗肿瘤药物 Source
供应商 高校/研究院合作
提供临床前CRO服务 Source
供应商 临床前CRO
提供药物发现和临床前研究服务 Source
供应商 临床前CRO
提供原料药及制剂CDMO服务 Source
供应商 CDMO

People who follow this company also follow

Competitors (Similar Companies)

“To develop high-quality biologics that are accessible and affordable f”
医药 生物医药 创新药 制药/药业
“专注于靶向肿瘤治疗小分子药物的研发”
“Providing solutions for personalized treatment and health management”
生命科学 生物信息 生物制药 干细胞
“Continuously innovating to bring patients medicines that significantly”
“Continuous innovation, safeguarding health”
“Accelerating global biologic drug R&D processes, reducing R&D costs, a”
“Research, development, and production of anti-tumor and surgical medic”
“A renowned enterprise in China's liver disease and anti-tumor fields”
制药/药业 生物制药 医药中间体 原料药
中间体 生产 原料药 中间体生产
“专门从事生物医药研发外包服务的高新技术企业”
“Promoting human health”
“Innovative chemical products and services provider in the drug researc”

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates